Home > Cardiology > ACC 2021 > Ischaemic Heart Disease > Rivaroxaban reduces total ischaemic events after peripheral artery revascularisation

Rivaroxaban reduces total ischaemic events after peripheral artery revascularisation

Presented By
Dr Rupert Bauersachs, Klinikum Darmstadt, Germany
Conference
ACC 2021
Trial
VOYAGER PAD
An analysis of the VOYAGER PAD trial showed that rivaroxaban (2.5 mg twice daily) reduced both first and subsequent adverse limb and cardiovascular events in patients with peripheral artery disease (PAD) and should therefore be considered as adjunctive therapy following lower extremity revascularisation (LER) [1,2]. Patients with PAD are known to have an elevated risk (1 in 5) of major adverse limb events (MALE) (i.e. acute limb ischaemia or major limb amputation due to a vascular cause) and major adverse cardiovascular events (MACE) following LER despite antiplatelet therapy. The previously published VOYAGER PAD (NCT02504216) results demonstrated that the direct oral anticoagulant rivaroxaban combined with usual care lowered the risk of first events [3]. VOYAGER PAD randomised 6,564 participants with PAD who had recently undergone LER to receive either 2.5 mg rivaroxaban twice daily (n=3...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on